Anita Tanner, PA
Medical · Oklahoma City, OKNPI 1346206331
Payments from drug & device makers
Across 35 payments — averaging $62.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$847
- Astellas Pharma US Inc$294
- Lilly USA, LLC$173
- Novo Nordisk$169
- Nalu Medical, Inc.$149
- Dexcom, Inc.$137
- plus $431 from 9 others
What the payments were for
- Food & beverage$2,13597%
- Education$663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $847 |
| Astellas Pharma US Inc | 4 | $294 |
| Lilly USA, LLC | 4 | $173 |
| Novo Nordisk | 4 | $169 |
| Nalu Medical, Inc. | 1 | $149 |
| Dexcom, Inc. | 2 | $137 |
| Regeneron Healthcare Solutions, Inc. | 1 | $104 |
| GSK | 1 | $99 |
| Otsuka America Pharmaceutical, Inc. | 1 | $98 |
| Exact Sciences | 2 | $35 |
| Insulet Corporation | 1 | $27 |
| Seqirus USA Inc | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| Abbott | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$367
- FARXIGA$356
- Nalu Neurostimulation System$149
- Veozah$118
- JARDIANCE$117
- Saxenda$116
- DEXCOM G7 GSS (161)$115
- DEXCOM STELO GLUCOSE BIOSENSOR$115
How this compares
$2,201 in reported general payments places this provider in the 75th percentile of 370 medical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $89,031 |
| EliquisApixaban | 40 | $60,483 |
| MounjaroTirzepatide | 16 | $34,148 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $33,902 |
| JardianceEmpagliflozin | 25 | $32,909 |
| FarxigaDapagliflozin Propanediol | 25 | $31,264 |
| JanuviaSitagliptin Phosphate | 12 | $20,435 |
| RexultiBrexpiprazole | 12 | $20,175 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $14,856 |
| Levemir FlexpenInsulin Detemir | 11 | $5,483 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $5,207 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $4,680 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,807 |
| Atorvastatin Calcium | 252 | $3,212 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $3,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $169 | $89,03174 claims |
| PfizerEliquis | $14 | $60,48340 claims |
| Lilly USA, LLCMounjaro | $173 | $34,14816 claims |
| GSKTrelegy Ellipta | $99 | $33,90232 claims |
| AstraZenecaFarxiga | $847 | $31,26425 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $98 | $20,17512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 370 medical providers in Oklahoma.
Other medical in Oklahoma City
- Mebin ThomasOklahoma City$323K
- Kristine MurrowOklahoma City$81K
- Katelyn PuryearOklahoma City$22K
- Kelly WalworthOklahoma City$15K
- Jere ClaunchOklahoma City$15K
- Vy TranOklahoma City$15K
- Jennifer MinshallOklahoma City$11K
- Lindee LedbetterOklahoma City$10K
- Christina HelmsOklahoma City$7K
- John ParmeleeOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.